CCP
AVEO

Clough Capital Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Clough Capital Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-104,800
Closed -$691K – 155
2021
Q2 		$691K Sell
104,800
-195,200
-65% -$1.35M 0.04% 114
2021
Q1 		$2.2M Buy
+300,000
New +$2.59M 0.1% 98

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Clough Capital Partners's AVEO Position: Q3 2021 in Review

Clough Capital Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2021, closing a stake of 104,800 shares — an estimated $691K sold.

Clough Capital Partners first reported a position in AVEO in Q1 2021 and held it in 2 quarters. The position peaked at $2.2M in Q1 2021. 52 funds tracked by Wall St. Rank hold AVEO as of Q3 2021.

  • Clough Capital Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Clough Capital Partners sold 104,800 AVEO Pharmaceuticals, Inc. shares in Q3 2021, an estimated $691K.
  • Clough Capital Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2021 and held it in 2 quarters.
  • Clough Capital Partners's AVEO Pharmaceuticals, Inc. position peaked at $2.2M in Q1 2021.
  • 52 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2021.

Based on Clough Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.